Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alberto Rivera Rosado

Orthopaedic Surgery Santurce, PR Medical Doctor

NPI 1720282726 CMS profile 213883

279 Calle Convento, Santurce, PR 00912

Open in the dashboard

General payments

$197,329

223 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alberto Rivera Rosado of Santurce, PR is reported in the CMS Open Payments database as having received $197,329 across 223 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,131 34
2024 General $12,404 12
2023 General $21,732 15
2022 General $36,920 24
2021 General $37,328 38
2020 General $11,698 9
2019 General $46,116 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alberto Rivera Rosado
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Alberto Rivera Rosado were reported at $31,131. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Alberto Rivera Rosado Orthopaedic Surgery median Middle half National median
2019 $46,116 $644 $140–$2,844 $163
2020 $11,698 $312 $75–$1,860 $114
2021 $37,328 $520 $117–$2,495 $132
2022 $36,920 $598 $128–$2,731 $149
2023 $21,732 $461 $128–$2,264 $160
2024 $12,404 $497 $134–$2,475 $164
2025 $31,131 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Exactech, Inc. $117,373 71 payments
  2. Zimmer Biomet Holdings, Inc. $34,858 51 payments
  3. Smith+Nephew, Inc. $29,693 53 payments
  4. Linvatec Corporation $11,510 9 payments
  5. Arthrex, Inc. $1,529 15 payments
  6. Encore Medical, LP $860 3 payments
  7. Johnson and Johnson International $347 5 payments
  8. Stryker Corporation $292 4 payments
  9. Wright Medical Technology, Inc. $269 3 payments
  10. FX Shoulder USA, Inc $196 1 payment
  11. Other $402 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $119,657 48 payments
  2. Travel and Lodging $47,017 63 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,520 3 payments
  4. Food and Beverage $10,205 103 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $9,000 4 payments
  6. Education $930 2 payments
Products named General payments · program years 2019–2025
  1. Equinoxe Orthopaedic $54,802 26 payments
  2. EQUINOXE Orthopaedic $47,403 37 payments
  3. Comprehensive Shoulder System $12,825 15 payments
  4. SUTUREFIX $11,454 13 payments
  5. EQUINOXE PHX SYSTEM $10,989 3 payments
  6. REGENESORB $8,648 6 payments
  7. SHOULDER MANUAL INSTRUMENTS $8,600 3 payments
  8. TENOLOK $7,800 2 payments
  9. HEALICOIL $6,080 6 payments
  10. HEALICOIL PK Shoulder $6,000 1 payment
  11. Other $38,481 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,557

Median for Orthopedic Surgery: 203

Drug cost

$83,199

Median for Orthopedic Surgery: $1,433

Branded share of claims

9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 121 $71,169
Gabapentin Generic 538 $3,894
Clindamycin Hcl Generic 281 $3,390
Doxycycline Hyclate Generic 245 $1,529
Methylprednisolone Generic 103 $921
Meloxicam Generic 133 $683
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $451
Alendronate Sodium Generic 63 $384
Diclofenac Sodium Generic 11 $293
Triamcinolone Acetonide Generic 26 $265

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Records

223 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record